Brian Birchler Net Worth

The estimated Net Worth of Brian Birchler is at least $2 Milhão dollars as of 15 April 2024. Brian Birchler owns over 1,875 units of Ionis Pharmaceuticals Inc stock worth over $2,001,504 and over the last 2 years Brian sold IONS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Brian Birchler IONS stock SEC Form 4 insiders trading

Brian has made over 4 trades of the Ionis Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Brian exercised 1,875 units of IONS stock worth $79,744 on 15 April 2024.

The largest trade Brian's ever made was exercising 12,080 units of Ionis Pharmaceuticals Inc stock on 16 January 2024 worth over $513,762. On average, Brian trades about 3,416 units every 46 days since 2023. As of 15 April 2024 Brian still owns at least 47,061 units of Ionis Pharmaceuticals Inc stock.

You can see the complete history of Brian Birchler stock trades at the bottom of the page.

What's Brian Birchler's mailing address?

Brian's mailing address filed with the SEC is 2855 GAZELLE COURT, , CARLSBAD, CA, 92010.

Insiders trading at Ionis Pharmaceuticals Inc

Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall, eMichael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.

What does Ionis Pharmaceuticals Inc do?

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.

Complete history of Brian Birchler stock trades at Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc executives and stock owners

Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Stanley Crooke,
  Executive Chairman of the Board of Directors
• Brett Monia,
  Chief Executive Officer, Director
• Richard Geary,
  Senior Vice President - Development
• Elizabeth Hougen,
  Senior Vice President, Finance and Chief Financial Officer
• Patrick O'Neil,
  Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
• Joan Herman,
  Director
• B. Lynne Parshall,
  Director
• Dr. Brett P. Monia Ph.D.,
  Founder, CEO & Director
• Dr. Stanley T. Crooke,
  Scientific Advisor
• Joseph Klein,
  Independent Director
• Joseph Wender,
  Independent Director
• Spencer Berthelsen,
  Independent Director
• Breaux Castleman,
  Independent Director
• Frederick Muto,
  Independent Director
• Michael Hayden,
  Independent Director
• Joseph Loscalzo,
  Independent Director
• Peter Reikes,
  Independent Director
• B. Lynne Parshall Esq., J.D.,
  Sr. Strategic Advisor & Director
• C. Frank Bennett,
  Chief Scientific Officer
• Dr. Richard S. Geary,
  Exec. VP & Chief Devel. Officer
• Elizabeth L. Hougen,
  Exec. VP of Fin. & CFO
• Patrick R. O'Neil Esq.,
  Chief Legal Officer, Gen. Counsel & Corp. Sec.
• Dr. Eric E. Swayze Ph.D.,
  Exec. VP of Research
• D. Wade Walke,
  Investor Relations
• Onaiza Cadoret-Manier,
  Chief Corporate Development and Commercial Officer
• Eric Swayze,
  Senior Vice President - Research
• Dr. C. Frank Bennett,
  Exec. VP & Chief Scientific Officer
• Darren Gonzales,
  Chief Accounting Officer & Sr. VP
• Joel Edwards,
  VP of Corp. Operations
• Damien Mc Devitt,
  Chief Business Officer
• Sarah Boyce,
  Chief Business Officer
• Joseph Baroldi,
  EVP, Chief Business Officer
• Kyle Jenne,
  EVP, Chf GL Pdt Str Ofcr
• Allene M. Diaz,
  Director
• Brian Birchler,
  EVP, Corp and Development Ops
• Eugene Schneider,
  EVP, Chf Clinical Develop Ofcr
• Michael J. Yang,
  Director